CS-866DM phase 3 clinical study: A double-blind controlled trial in patients with diabetic nephropathy and overt proteinuria secondary to type 2 diabetes mellitus.

Trial Profile

CS-866DM phase 3 clinical study: A double-blind controlled trial in patients with diabetic nephropathy and overt proteinuria secondary to type 2 diabetes mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2017

At a glance

  • Drugs Olmesartan medoxomil (Primary)
  • Indications Diabetic nephropathies; Proteinuria; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ORIENT
  • Most Recent Events

    • 06 Dec 2011 Actual completion date changed to 01 Feb 2008 after recommendations from IDMC suggested primary endpoint was reached, according to report in Diabetologia.
    • 13 Oct 2011 Results published in the Diabetologia.
    • 01 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top